Pelage Pharmaceutical, a Los Angeles, CA-based clinical-stage regenerative medicine company focused on hair loss, raised $14M in Series A-1 funding.
The round was led by GV.
The company intends to use the funds to accelerate its Phase 2 clinical program.
Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing novel treatments for hair loss including androgenetic alopecia and chemotherapy-induced-alopecia. With a focus on molecular and stem cell biology, it is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body’s ability to naturally grow hair. Its lead program, PP405, is currently in clinical trials.
PP405 is a novel, non-invasive, topical small molecule designed to reactivate dormant hair follicle stem cells and restart hair growth. Through a regenerative medicine approach, the treatment focuses on addressing the metabolic processes that regulate the activation and inactivation phases of hair follicle stem cells. Early results from a Phase 1 trial show that PP405 was well-tolerated and demonstrated statistically significant activation of hair follicle stem cells. In 2018, Pelage Pharmaceuticals licensed the intellectual property to PP405 and related topical small molecules from the University of California. PP405 is currently in Phase 2a clinical evaluation to assess safety and preliminary efficacy in adults with androgenetic alopecia (NCT06393452).
FinSMEs
13/08/2024